Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib vs Crizotinib in first-line ALK-positive NSCLC
NCT03052608Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Apr 2017
- Primary completion
- Mar 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 23
01
Overview
A Phase 3 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Apr 2017; status: active, not recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03052608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052608.